Eledon Pharmaceuticals, Inc.

ELDN Healthcare Biotechnology

In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.

2.27 0.02 +0.89%
Market cap
$190.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
7.40 12.42 14.41 9.19 20.07 46.57 7.54 5.63 13.19 0.30
Net Debt/EBITDA
1.60 1.99 1.20 1.43 2.31 6.25 0.63 0.92 1.32 (0.46)
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 288.21%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (1.28)
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
1.37 1.31 0.34 0.32 0.84 0.67 0.87 0.85 1.14 0.87
Capex/Depreciation
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.36 0.03
ROE
(63.56%) (518.40%) (652.92%) (70.89%) (19.46%) (22.80%) (133.66%) (82.87%) (156.79%) (19.17%)
ROA
(26.34%) (27.16%) (128.16%) (66.81%) (18.77%) (21.92%) (114.54%) (74.19%) (118.76%) (16.35%)
ROIC
(1,511.24%) 0.00% 0.00% (198.99%) (29.11%) (15.11%) (1,488.41%) (578.13%) (381.60%) 0.00%
Return on Tangible Assets
(38.87%) (27.38%) (223.11%) (165.84%) (41.11%) (20.16%) (185.01%) (119.64%) (74.59%) 208.13%
Average Days of Receivables
— — — — — 0.00 0.00 — — —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.29 0.25 0.00 0.11 0.09 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.76) (0.97) (1.61) (1.99) (1.95) (10.48) (21.12) (23.75) (57.41) (231.08)
Cash per Share
1.63 2.89 2.08 3.95 5.72 78.70 13.40 25.91 66.52 52.44
Shareholders Equity per Share
1.67 2.43 0.29 5.89 11.07 131.35 14.43 28.94 74.79 (126.85)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.67 2.43 0.29 5.89 11.07 131.35 14.43 28.94 74.79 (126.85)
Free Cash Flow
(62.34) (47.27) (39.53) (28.42) (28.91) (15.21) (13.86) (11.89) (14.93) (4.92)
Working Capital
117.34 132.15 52.23 53.04 83.95 113.15 8.65 11.74 17.56 (2.75)
Capital Expenditures
— — — — — — — — 0.01 0.00
Net Current Asset Value
103.46 84.47 (25.73) 50.91 81.79 109.04 8.51 11.74 17.56 (2.75)
Other line items
Quick Ratio
7.27 12.11 13.12 8.71 19.28 45.99 6.65 5.12 12.02 0.29
Depreciation/Fixed assets
— 0.00 0.00 0.00 0.00 0.00 409.80 0.79 0.88 1.13
Cash ROIC
(23.08%) (18.30%) (67.79%) (20.22%) (11.62%) (4.99%) (75.90%) (43.30%) (40.63%) (264.34%)
Accounts Receivable Turnover
— — — — — 0.00 0.00 — — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
(0.76) (0.97) (1.61) (1.99) (1.95) (10.48) (21.12) (23.75) (57.44) (231.13)
Capex per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.05
Average Receivables
— — — — — 0.18 0.18 — — —
Average Payables
4.73 3.40 1.58 2.01 1.59 0.85 0.51 0.55 0.38 0.77
Average Assets
173.21 133.24 90.93 131.67 183.87 104.06 13.98 18.96 11.04 34.59
Average Common Equity
71.77 6.98 17.85 124.09 177.30 100.03 11.98 16.97 8.37 29.50
Capex to Sales
— — — — — — — — 0.00 0.00

Fold the line items

Columns are period end dates